- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Healthy potentially undervalued
Hong Kong Pharmaceuticals & Biotech Healthy potentially undervalued
Results
10
Companies which are potentially undervalued and in an acceptable financial position.
10 companies
Innovent Biologics
Market Cap: HK$150.9b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$86.70
7D
-3.6%
1Y
-12.2%
China Resources Pharmaceutical Group
Market Cap: HK$30.5b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.86
7D
0.4%
1Y
-8.5%
United Laboratories International Holdings
Market Cap: HK$18.0b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$9.11
7D
1.3%
1Y
-38.6%
3SBio
Market Cap: HK$41.9b
An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.
1530
HK$16.83
7D
-1.8%
1Y
-47.9%
Shanghai Junshi Biosciences
Market Cap: HK$37.3b
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.
1877
HK$18.25
7D
-1.5%
1Y
-43.3%
Duality Biotherapeutics
Market Cap: HK$17.2b
A clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally.
9606
HK$190.10
7D
-16.5%
1Y
-51.0%
Everest Medicines
Market Cap: HK$8.8b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$25.06
7D
1.0%
1Y
-64.6%
InnoCare Pharma
Market Cap: HK$27.0b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$13.35
7D
-5.3%
1Y
-30.6%
Grand Pharmaceutical Group
Market Cap: HK$17.7b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
512
HK$5.07
7D
-1.1%
1Y
-37.7%
China Medical System Holdings
Market Cap: HK$29.1b
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
867
HK$12.01
7D
-1.1%
1Y
-8.5%